Browse News
Filter News
Found 86 articles
-
BetterLife To Present BETR-001 Preclinical Data at the 2023 Annual Meeting of the Society of Biological Psychiatry (SOBP) in San Diego, California
4/25/2023
BetterLife Pharma Inc. announced that its scientific collaborators, Drs. Vern Lewis and Argel Aguilar-Valles from Carleton University’s Department of Neuroscience in Ottawa, Canada, will present on the anti-depressant and anti-anxiety activity of BetterLife’s 2-bromo-LSD at the upcoming SOBP Conference, being held April 27-29, 2023 at San Diego, California, USA.
-
BetterLife To Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference
4/20/2023
BetterLife Pharma Inc. is pleased to announce that Dr. Ahmad Doroudian, Chief Executive Officer, and Dr. Hooshmand Sheshbaradaran, Chief Operating Officer, will present at the upcoming Bloom Burton Healthcare Investor Conference on Wednesday April 26, 2023 in Toronto, Ontario, Canada.
-
BetterLife To Present BETR-001 Preclinical Data at the 61ST Annual Meeting of the American College of Neuropsychopharmacology (ACNP) in Phoenix, Arizona
12/2/2022
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU) today announced that one of its scientific collaborators, Dr. Argel Aguilar-Valles from Carleton University’s Department of Neuroscience (Ottawa, Canada), will present on the anti-depressant activity of 2-bromo-LSD (“BETR-001”), the Company’s lead compound, at the upcoming ACNP Conference being held December 4 to 7 at Phoenix, Arizona, USA.
-
BetterLife Files Comprehensive Patent for BETR-001 and Other LSD Derivatives
9/27/2022
BetterLife Pharma Inc. is pleased to announce filing of a PCT patent application along with a U.S. application for lysergic acid diethylamide derivatives, including 2-bromo-LSD.
-
Russian researchers announced a new Sputnik V vaccine against the Delta and Omicron variants of COVID-19, AB Science files for conditional marketing approval of its ALS drug in the EU and much more.
-
BetterLife Lead Drug (BETR-001) Promotes Structural Neural Plasticity with Possible Nootropic Effects Similar to That of LSD Without Hallucinogenic Side Effects
8/24/2022
BetterLife Pharma Inc., is an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders.
-
Osteoarthritis Assistive Devices Market is Predicted to Experience Noticeable Growth by 2027
8/19/2022
Wilmington, Delaware, United States, Transparency Market Research Inc. – Osteoarthritis is a degenerative joint problem and the most widely recognized kind of joint pain.
-
Olink said the measurement of proteins at "population scale" provides the ability to improve the understanding of underlying mechanisms of diseases.
-
BetterLife To Present BETR-001 Preclinical Data at the Upcoming Federation of European Neuroscience Societies (FENS) Forum
6/21/2022
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, today announced that an abstract submitted on the anti-depressant activity of its lead compound 2-bromo-LSD (“BETR-001”) was accepted for poster presentation at the upcoming FENS Forum.
-
BetterLife To Present BETR-001 Preclinical Data at the Upcoming Canadian Association for Neuroscience Conference
4/21/2022
BetterLife Pharma Inc. announced that an abstract on the preclinical data on anti-depressant activity of its lead compound 2-bromo-LSD was accepted for presentation at the upcoming Canadian Association for Neuroscience Conference, being held May 12-15 in Toronto, Canada.
-
Biopharma and life sciences organizations from across the globe provide updates on their businesses and pipelines.
-
BetterLife’s BETR-001 Demonstrates BETR-001 Anti-depressant Activity in Preclinical Models of Depression
4/6/2022
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, is pleased to announce it has obtained additional positive data confirming the anti-depressant activity of its lead compound 2-bromo-LSD (“BETR-001”) in preclinical models of depression.
-
BetterLife Obtains In Vivo PK Data for BETR-001 Confirming its Bioavailability in Brain
3/16/2022
BetterLife Pharma Inc. is pleased to announce it has obtained the first set of positive in vivo pharmacokinetic data confirming the bioavailability of its lead compound BETR-001 in the brain and plasma of treated mice.
-
BetterLife Lead Drug (BETR-001) Promotes Structural Neural Plasticity in Preclinical Model
2/15/2022
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of 2nd generation non-hallucinogenic psychedelic analogs...
-
BetterLife Receives FDA Response On Its Pre-IND Application For Major Depressive Disorder (MDD) Treatment With BETR-001
1/20/2022
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), is pleased to announce it has received a written response from the U.S. Food and Drug Administration (FDA) to its pre-investigational new drug (pre-IND) application for the treatment of MDD with BETR-001.
-
BetterLife’s Wholly-Owned Subsidiary, Altum Pharmaceuticals, Obtains Non-Dilutive Financing Commitment From Strategic Investor!
12/22/2021
BetterLife today announced that its wholly-owned subsidiary, Altum Pharmaceuticals Inc. (“Altum”), has signed an agreement with an European-based investor group to complete a non-brokered financing of up to US$5.0 million by way of private placement of Altum’s common shares.
-
BetterLife Obtains Positive TD-0148A Data in Preclinical Models of Depression
12/9/2021
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), is pleased to announce it has obtained the first set of positive data showing anti-depressant properties of its lead compound, 2-bromo-LSD (“TD-0148A”) in animal depression models, as part of its collaboration with the laboratory of Dr. Argel Aguilar-Valles at Carleton University’s (Carleton) Department of Neuroscience.
-
Heading out of November and into December, plenty of companies had clinical trial news to report. Here’s a look.
-
H.C. Wainwright 2nd Annual Psychedelics Conference, BACK TO THE FUTURE!
12/3/2021
BetterLife Pharma Inc. is pleased to announce that Dr. Ahmad Doroudian will be participating in the H.C. Wainwright 2nd Annual Psychedelics Conference.
-
BetterLife Successfully Completes Phase 1 and Initiates Phase 2 Clinical Trials with Interferon Alpha-2b in COVID-19 Patients in Chile
11/29/2021
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU) today announced that its wholly owned subsidiary, Altum Pharmaceuticals Inc. (“Altum”), and Pontificia Universidad Católica de Chile have successfully completed the Phase 1 portion of the Phase 1-2 randomized placebo controlled trial.